Baxter International Dirección

Dirección controles de criterios 1/4

El CEO de Baxter International's es Joe Almeida , nombrado en Jan 2016, tiene una permanencia de 8.25 años. compensación anual total es $13.79M, compuesta por 9.4% salario y 90.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de €21.84M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 4.2 años, respectivamente.

Información clave

Joe Almeida

Chief Executive Officer (CEO)

US$13.8m

Compensación total

Porcentaje del salario del CEO	9.4%
Permanencia del CEO	8.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joe Almeida en comparación con los beneficios de Baxter International?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$14m	US$1m	-US$76m
Sep 30 2023	n/a	n/a	US$225m
Jun 30 2023	n/a	n/a	-US$3b
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$14m	US$1m	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	US$876m
Mar 31 2022	n/a	n/a	US$992m
Dec 31 2021	US$16m	US$1m	US$1b
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$16m	US$1m	US$1b
Sep 30 2020	n/a	n/a	US$911m
Jun 30 2020	n/a	n/a	US$924m
Mar 31 2020	n/a	n/a	US$991m
Dec 31 2019	US$14m	US$1m	US$1b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$795m
Mar 31 2018	n/a	n/a	US$840m
Dec 31 2017	US$15m	US$1m	US$609m

Compensación vs. Mercado: La compensación total de Joe($USD13.79M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Joe ha aumentado mientras la empresa no es rentable.

CEO

Joe Almeida (61 yo)

8.3yrs

Permanencia

US$13,786,671

Compensación

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jose Almeida	Chairman of the Board	8.3yrs	US$13.79m	0.11% $ 19.3m
Joel Grade	Executive VP & CFO	less than a year	US$5.37m	0% $ 0
Heather Knight	Executive VP & Group President of Medical Products and Therapies	1.2yrs	US$4.86m	0.031% $ 5.4m
Alok Sonig	Executive VP & Group President of Pharmaceuticals	1.8yrs	US$3.87m	0.0016% $ 269.6k
Christopher Toth	Executive VP & Group President of Kidney Care	less than a year	US$9.64m	0% $ 0
Tobi Karchmer	Senior VP and Chief Medical & Scientific Officer	1.3yrs	sin datos	sin datos
Clare Trachtman	Vice President of Investor Relations	no data	sin datos	sin datos
David Rosenbloom	Executive VP & General Counsel	2.1yrs	US$5.66m	0.0014% $ 241.9k
Stacey Eisen	?Senior Vice President	no data	sin datos	sin datos
Jeanne Mason	?Executive VP & Chief Human Resources Officer	7yrs	US$4.14m	0.037% $ 6.4m
James Borzi	Executive VP & Chief Supply Chain Officer	4.3yrs	sin datos	0.0030% $ 516.7k
Reazur Rasul	Executive VP & Group President of Healthcare Systems and Technologies	2.3yrs	sin datos	0.021% $ 3.7m

2.0yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BTL no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jose Almeida	Chairman of the Board	8.3yrs	US$13.79m	0.11% $ 19.3m
Stephen Rusckowski	Independent Director	less than a year	US$197.82k	0.00061% $ 105.4k
Robert Parkinson	Chairman Emeritus	8.3yrs	US$17.88m	sin datos
Peter Wilver	Independent Director	2yrs	US$349.64k	0.0014% $ 247.1k
Stephen Newman Oesterle	Independent Director	7.3yrs	US$373.98k	0.0043% $ 739.6k
Patricia Morrison	Independent Director	5.3yrs	US$364.98k	0.0030% $ 518.4k
Nancy Schlichting	Independent Director	2.4yrs	US$363.00k	0.00015% $ 25.9k
Catherine Smith	Independent Director	7.3yrs	US$367.31k	0.0032% $ 558.1k
David Shafer	Lead Independent Director	2yrs	US$382.31k	0.0014% $ 245.4k
David Wilkes	Independent Director	3.3yrs	US$357.00k	0.00054% $ 93.3k
William Ampofo	Independent Director	less than a year	US$226.35k	0.00076% $ 131.3k
Amy Wendell	Independent Director	5.3yrs	US$352.98k	sin datos

4.3yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de BTL se considera experimentada (4.2 años de antigüedad promedio).

Baxter International Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc. Announces Management Appointments

Baxter International Inc. Announces Board Changes

High number of new directors

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Recent updates

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

First quarter 2024 earnings released: EPS: US$0.073 (vs US$0.002 loss in 1Q 2023)

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Upcoming dividend of US$0.29 per share

Fourth quarter dividend of US$0.29 announced

Full year 2023 earnings released: US$0.15 loss per share (vs US$4.83 loss in FY 2022)

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Now 21% overvalued after recent price rise

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Upcoming dividend of US$0.29 per share at 3.2% yield

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Third quarter 2023 earnings released: EPS: US$0.095 (vs US$5.83 loss in 3Q 2022)

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Baxter International Inc. Announces Management Appointments

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces Board Changes

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.36 profit in 2Q 2022)

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

High number of new directors

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

First quarter 2023 earnings released: EPS: US$0.087 (vs US$0.14 in 1Q 2022)

Baxter International Inc. Announces Management Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023

Full year 2022 earnings released: US$4.83 loss per share (vs US$2.56 profit in FY 2021)

Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022

Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer

Baxter Introduces ExactaMix Pro Automated Compounder

Upcoming dividend of US$0.29 per share

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023

Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022

Third quarter 2022 earnings released: US$5.83 loss per share (vs US$0.90 profit in 3Q 2021)

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

Upcoming dividend of US$0.29 per share

Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021)

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Baxter International Inc. Announces Executive Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on October 3, 2022

Upcoming dividend of US$0.29 per share

Baxter International Inc. Announces Board Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2022

First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.59 in 1Q 2021)

Baxter International Inc. Announces Findings of an Observational Study on Data from the Starling Registry

Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

Baxter International Inc., Annual General Meeting, May 03, 2022

Baxter International Inc. Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Baxter International Inc. Provides Earnings Guidance for the First Quarter and Year of 2022

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on April 1, 2022

Upcoming dividend of US$0.28 per share

Third quarter 2021 earnings released: EPS US$0.90 (vs US$0.70 in 3Q 2020)

Baxter International Inc. Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

Baxter Reportedly in Advanced Talks to Acquire Hill-Rom for About $10 Billion

Upcoming dividend of US$0.28 per share

Second quarter 2021 earnings released: EPS US$0.59 (vs US$0.48 in 2Q 2020)